Piramal Pharma Limited has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organisation (CDMO) focused on vaccines and biologics. The transaction, completed on August 18, 2026, involved an aggregate cash consideration of ₹76 crore, or approximately $7.95 million. Following the acquisition, Piramal Pharma now holds 74% of the equity in Yapan Bio, making the company a subsidiary of Piramal Pharma.
The acquisition strengthens Piramal Pharma Solutions’ (PPS) capabilities in biologics and large-molecule development and manufacturing. Yapan Bio will continue to operate within the PPS business, which provides integrated CDMO services to pharmaceutical and biotechnology companies across the drug development lifecycle.
Yapan Bio brings specialised capabilities in vaccines and biologics to Piramal Pharma’s global network. The company said integrating these capabilities will allow PPS to offer customers a broader range of services and strengthen its ability to develop and manufacture complex biologic therapies.
The transaction also supports ADCelerate, PPS’s integrated platform for Phase I antibody-drug conjugate development. The platform is designed to bring together research and development and GMP manufacturing through a fixed-price model, with the aim of completing Phase I ADC development in as little as 12 months. Piramal Pharma said the addition of Yapan Bio’s capabilities will further strengthen ADCelerate and support the development and manufacturing of complex therapies.
Peter DeYoung, CEO, Piramal Global Pharma, said the investment supports the company’s long-term growth strategy while advancing its focus on patients. He said integrating Yapan Bio’s specialised expertise into Piramal Pharma’s global network would help pharmaceutical partners address growing demand for complex biologics and improve access to therapies.Yapan Bio’s capabilities complement PPS’s existing services across drug discovery, process development, pharmaceutical development, clinical trial supplies, commercial manufacturing and specialised drug products.
The company operates an integrated network of development and manufacturing facilities across North America, Europe and Asia. Its service portfolio includes development and manufacturing of APIs and finished dosage forms, highly potent APIs, antibody-drug conjugates, sterile products, peptides and potent solid oral formulations. The business also provides development and manufacturing services for biologics, vaccines and gene therapies.
Piramal Pharma Limited operates through three main businesses: Piramal Pharma Solutions, Piramal Critical Care and Piramal Consumer Healthcare. The company has 17 global development and manufacturing facilities and a distribution network spanning more than 100 countries.
Piramal Pharma Solutions provides services across the pharmaceutical product lifecycle, supporting customers from early-stage development through clinical and commercial manufacturing. The acquisition of Yapan Bio adds further biologics expertise to this global platform and expands its capabilities in an increasingly important segment of the pharmaceutical industry.
